We are live on
!
Find out more
Entrada Therapeutics
TRDA
TRDA
56 hedge funds and large institutions have $390M invested in Entrada Therapeutics in 2023 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 18 increasing their positions, 11 reducing their positions, and 12 closing their positions.
New
Increased
Maintained
Reduced
Closed
64% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 11
33% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 12
8% more capital invested
Capital invested by funds: $361M → $390M (+$28.8M)
8% more funds holding
Funds holding: 52 → 56 (+4)
2.33% more ownership
Funds ownership: 75.24% → 77.57% (+2.3%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
Holders
56
Holders Change
+4
Holders Change %
+7.69%
% of All Funds
0.88%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.06%
New
16
Increased
18
Reduced
11
Closed
12
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
BlackRock
New York
|
+$16.4M |
| 2 |
State Street
Boston,
Massachusetts
|
+$4.5M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$2.99M |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$2.21M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.12M |
Top Sellers
| 1 |
RG
Redmile Group
San Francisco,
California
|
-$7.16M |
| 2 |
LCM
Laurion Capital Management
New York
|
-$2.89M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$2.85M |
| 4 |
Millennium Management
New York
|
-$2.47M |
| 5 |
Jane Street
New York
|
-$1.07M |
